Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial

(2016) H. W. Rodbard et al.   DIABETES OBESITY & METABOLISM

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

(2015) Shizuka Kaneko et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

(2014) Gregory R. Fulcher et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

(2014) Tim Heise et al.   Diabetes Therapy

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

(2013) Y. Onishi et al.   DIABETES OBESITY & METABOLISM

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

Timing of food intake predicts weight loss effectiveness

(2013) M Garaulet et al.   INTERNATIONAL JOURNAL OF OBESITY

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

(2012) K. Khunti et al.   DIABETES OBESITY & METABOLISM

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

(2011) M. Evans et al.   DIABETES OBESITY & METABOLISM

Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

(2011) A. E. Pontiroli et al.   DIABETES OBESITY & METABOLISM

Treatment regimens with insulin analogues and haemoglobin A1c target of

(2010) Dario Giugliano et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

(2009) D. S. Lasserson et al.   DIABETOLOGIA

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus

(2008) D. Raccah   DIABETES OBESITY & METABOLISM